Cilostazol, a phosphodiesterase inhibitor, prevents no-reflow and hemorrhage in mice with focal cerebral ischemia

Experimental Neurology

Volumn 233, Issue 1, 2012, Pages 523-533

  Hase, Yoshiki ^a   Okamoto, Yoko ^a   Fujita, Youshi ^a   Kitamura, Akihiro ^a   Nakabayashi, Hitomi ^a   Ito, Hidefumi ^a   Maki, Takakuni ^a   Washida, Kazuo ^a   Takahashi, Ryosuke ^a   Ihara, Masafumi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cilostazol; Focal cerebral ischemia; Matrix metalloproteinase; Tissue plasminogen activator; Virchow's triad

Indexed keywords

CILOSTAZOL; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL DENSITY; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; HEMODYNAMICS; HISTOPATHOLOGY; LEUKOCYTE AGGREGATION; MICROGLIA; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR PERFORMANCE; MOUSE; NEUROIMAGING; NEUROPROTECTION; NO REFLOW PHENOMENON; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPERFUSION INJURY; THROMBOCYTE AGGREGATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD; BRAIN; BRAIN EDEMA; BRAIN ISCHEMIA; CALCIUM-BINDING PROTEINS; CEREBROVASCULAR CIRCULATION; DEXTRANS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FLUORESCEIN-5-ISOTHIOCYANATE; HEMORRHAGE; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER-DOPPLER FLOWMETRY; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; MOTOR ACTIVITY; PHOSPHODIESTERASE INHIBITORS; REPERFUSION; STATISTICS, NONPARAMETRIC; TETRAZOLES; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84856212654     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.11.038     Document Type: Article

References (33)

1. Abumiya T., Fitridge R., Mazur C., Copeland B.R., Koziol J.A., Tschopp J.F., Pierschbacher M.D., del Zoppo G.J. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000, 31:1402-1409. discussion 1409-1410.
2. Alexandrov A.V., Grotta J.C. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002, 59:862-867.
3. Alexandrov A.V., Hall C.E., Labiche L.A., Wojner A.W., Grotta J.C. Ischemic stunning of the brain: early recanalization without immediate clinical improvement in acute ischemic stroke. Stroke 2004, 35:449-452.
4. Chan P.H. Oxygen radicals in focal cerebral ischemia. Brain Pathol. 1994, 4:59-65.
5. Chen Y., Ito A., Takai K., Saito N. Blocking pterygopalatine arterial blood flow decreases infarct volume variability in a mouse model of intraluminal suture middle cerebral artery occlusion. J. Neurosci. Methods 2008, 174:18-24.
6. Choi J.M., Shin H.K., Kim K.Y., Lee J.H., Hong K.W. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J. Pharmacol. Exp. Ther. 2002, 300:787-793.
7. del Zoppo G.J. Virchow's triad: the vascular basis of cerebral injury. Rev. Neurol. Dis. 2008, 5(Suppl. 1):S12-S21.
8. del Zoppo G.J., Hallenbeck J.M. Advances in the vascular pathophysiology of ischemic stroke. Thromb. Res. 2000, 98:73-81.
9. FitzGerald G.A. Dipyridamole. N. Engl. J. Med. 1987, 316:1247-1257.
10. Fujita Y., Lin J.X., Takahashi R., Tomimoto H. Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats. Brain Res. 2008, 1203:170-176.
11. Fujita Y., Ihara M., Ushiki T., Hirai H., Kizaka-Kondoh S., Hiraoka M., Ito H., Takahashi R. Early protective effect of bone marrow mononuclear cells against ischemic white matter damage through augmentation of cerebral blood flow. Stroke 2010, 41:2938-2943.
12. Gerber J., Raivich G., Wellmer A., Noeske C., Kunst T., Werner A., Bruck W., Nau R. A mouse model of Streptococcus pneumoniae meningitis mimicking several features of human disease. Acta Neuropathol. 2001, 101:499-508.
13. Gotoh F., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., Otomo E., Shinohara Y., Itoh E., Matsuda T., Sawada T., Yamaguchi T., Nishimaru K., Ohashi Y. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J. Stroke Cerebrovasc. Dis. 2000, 9:147-157.
14. Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006, 367:1665-1673.
15. Huang Y., Cheng Y., Wu J., Li Y., Xu E., Hong Z., Li Z., Zhang W., Ding M., Gao X., Fan D., Zeng J., Wong K., Lu C., Xiao J., Yao C. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008, 7:494-499.
16. Ishiguro M., Mishiro K., Fujiwara Y., Chen H., Izuta H., Tsuruma K., Shimazawa M., Yoshimura S., Satoh M., Iwama T., Hara H. Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA. PLoS One 2010, 5:e15178.
17. Ito H., Hashimoto A., Matsumoto Y., Yao H., Miyakoda G. Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. J. Cereb. Blood Flow Metab. 2010, 30:343-351.
18. Kim K.Y., Shin H.K., Choi J.M., Hong K.W. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 2002, 300:709-715.
19. Kollmar R., Henninger N., Bardutzky J., Schellinger P.D., Schabitz W.R., Schwab S. Combination therapy of moderate hypothermia and thrombolysis in experimental thromboembolic stroke-an MRI study. Exp. Neurol. 2004, 190:204-212.
20. Komine-Kobayashi M., Chou N., Mochizuki H., Nakao A., Mizuno Y., Urabe T. Dual role of Fcgamma receptor in transient focal cerebral ischemia in mice. Stroke 2004, 35:958-963.
21. Kothari R.U., Brott T., Broderick J.P., Barsan W.G., Sauerbeck L.R., Zuccarello M., Khoury J. The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996, 27:1304-1305.
22. Lee J.H., Kim K.Y., Lee Y.K., Park S.Y., Kim C.D., Lee W.S., Rhim B.Y., Hong K.W. Cilostazol prevents focal cerebral ischemic injury by enhancing casein kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J. Pharmacol. Exp. Ther. 2004, 308:896-903.
23. Liu Y., Shakur Y., Yoshitake M., Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc. Drug Rev. 2001, 19:369-386.
24. Maddahi A., Chen Q., Edvinsson L. Enhanced cerebrovascular expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 via the MEK/ERK pathway during cerebral ischemia in the rat. BMC Neurosci. 2009, 10:56.
25. Ohlstein E.H., Storer B., Fujita T., Shebuski R.J. Tissue-type plasminogen activator and streptokinase induce platelet hyperaggregability in the rabbit. Thromb. Res. 1987, 46:575-585.
26. Shinohara Y., Katayama Y., Uchiyama S., Yamaguchi T., Handa S., Matsuoka K., Ohashi Y., Tanahashi N., Yamamoto H., Genka C., Kitagawa Y., Kusuoka H., Nishimaru K., Tsushima M., Koretsune Y., Sawada T., Hamada C. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010, 9:959-968.
27. Tanaka K., Gotoh F., Fukuuchi Y., Amano T., Uematsu D., Kawamura J., Yamawaki T., Itoh N., Obara K., Muramatsu K. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke 1989, 20:668-673.
28. Tanaka Y., Tanaka R., Liu M., Hattori N., Urabe T. Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia. Neuroscience 2010, 171:1367-1376.
29. Tsai C.S., Lin F.Y., Chen Y.H., Yang T.L., Wang H.J., Huang G.S., Lin C.Y., Tsai Y.T., Lin S.J., Li C.Y. Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J. Cell. Biochem. 2008, 103:54-66.
30. Uematsu D., Greenberg J.H., Reivich M., Hickey W.F. Direct evidence for calcium-induced ischemic and reperfusion injury. Ann. Neurol. 1989, 26:280-283.
31. von Kummer R., Bourquain H., Bastianello S., Bozzao L., Manelfe C., Meier D., Hacke W. Early prediction of irreversible brain damage after ischemic stroke at CT. Radiology 2001, 219:95-100.
32. Wang X., Lee S.R., Arai K., Tsuji K., Rebeck G.W., Lo E.H. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 2003, 9:1313-1317.
33. Zhang L., Schallert T., Zhang Z.G., Jiang Q., Arniego P., Li Q., Lu M., Chopp M. A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J. Neurosci. Methods 2002, 117:207-214.